Product
MCS110
1 clinical trial
1 indication
Indication
Triple Negative Breast CancerClinical trial
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast CancerStatus: Terminated, Estimated PCD: 2023-02-06